作者: Aniruddha Sengupta , Sanghamitra Mylavarapu , Smita Kumari , Samad Hossain , Nimish Gupta
DOI: 10.1200/JCO.2015.33.28_SUPPL.153
关键词: Surgery 、 Triple-negative breast cancer 、 Treatment options 、 Oncology 、 Platinum chemotherapy 、 Medicine 、 Median survival 、 Internal medicine 、 Breast cancer
摘要: 153 Background: Triple-negative breast cancer (TNBC) accounts for 15-20% of patients, with a median survival 13 months and limited treatment options. Recent studies have indicated ...